BEARD BROS PHARMS

Nearly Half of U.S Thinks Psychedelics Should be Legal for Mental Health Conditions

us thinks psychedelics legal mental health

According to a recent VeryWellMind survey, 46% of Americans favor making some psychedelic drugs legal for treating mental illnesses, provided that they are used under the guidance of a medical or mental health expert.

For decades, psychedelics like MDMA, LSD, and magic mushrooms have been unfairly vilified. However, their significance in managing complex mental health diseases has come to light in recent years. Given how difficult it is for those who suffer from mental health illnesses to lead regular lives, this is of utmost importance. Mental illness is one of the most costly medical disorders to treat globally.

Furthermore, standard medications for mental health don’t provide any alleviation for the millions of people who take them. Conditions resistant to treatment make a recovery from them much more difficult, which is why it was crucial to legalize psychedelics.

Increasing Acceptance

Although psychedelics are a “new” treatment in Western medicine, indigenous tribes have used them for thousands of years for healing and spiritual purposes. It’s crucial to comprehend the complex history and the potential for cultural appropriation if modern advances in psychedelic medicine overlook that history. Thankfully, more and more people are becoming aware of these medications’ advantages. They are no longer seen as the recreational drugs that our grandparents used to get high in the 1960s and 1970s. Americans aware of the benefits of psychedelic drugs concur that they are a form of medicine. Although there is still much to be done to improve accessibility and awareness, we are making progress.

In August 2022, a survey by VeryWellMind questioned almost 1,800 American adults about their views on psychedelics. Nearly half of Americans are receptive to employing psychedelics to treat mental health issues despite the knowledge and accessibility disparities. Upon professional administration or FDA approval, one in three Americans said they would be more receptive to accepting psychedelic-assisted treatment. For spiritual usage, 28% of respondents indicated favor of legalizing psychedelics, while 26% would support recreational use.

According to our poll, consumers may embrace the option to experiment with psychedelics as part of their treatment. One in every five participants in therapy stated they would consider psychedelics since other treatment approaches had left them feeling discouraged, indicating a general interest in alternative treatment choices. When it comes to psychedelics, Americans are wary but intrigued. Improved scientific and psychological understanding of these medications’ effects, hazards, and potential benefits will be the first step toward broader acceptance, further legalization, and, eventually, normalization as a mental health treatment option when appropriate.

Increasing Acceptance

A Track Filled With Hurdles

Some psychedelics have been decriminalized or legalized in a few states and countries. They are also widely available in some places, allowing adults to quickly get these medications and microdose as needed or even seek professional support to utilize them under medical supervision.

There’s no denying it: psychedelics are everywhere these days, even if they’re not entirely legal. You can even get shroom chocolates or ketamine online and deliver them to your house. Big corporations are recognizing its benefits and profitability and investing billions of dollars in researching and developing psychedelic-based medications.

Even though most states have already legalized marijuana in one way or another, the federal government continues to reject the medical value of psychedelics as they do with cannabis. Some of the most renowned colleges in the world are investing significant money in additional research, particularly to examine psilocybin, LSD, MDMA, and ketamine. It shouldn’t be surprising that most of this research has positive results for treating mental illness.

For the time being, like cannabis, all major psychedelics are classified as Schedule 1 drugs, except for ketamine. It is hoped that the clinical studies being carried out to demonstrate their advantages and usefulness will assist in paving the way for legalization. Equally crucial is decriminalization, which is often the first step toward complete legalization.

The stigma surrounding psychedelics will gradually disappear as more people understand them as a result of expanding the study. If all goes according to plan, the psychedelic business might be worth $6.85 billion by 2027.

A Track Filled With Hurdles


There is no denying that psychedelics are rapidly gaining popularity. People, scientists, and even Big Pharma are beginning to realize how effectively they can transform people’s lives. When you look at the recent poll results compared to the previous 5-10 years, it’s evident that psychedelics are well on their way to normalcy. Psychedelics may one day have the same legal standing as alcohol, which would be much better for everyone than alcohol ever was.

Enjoyed that first hit? Come chill with us every week at the Friday Sesh for a freshly packed bowl of the week’s best cannabis news!

Leave a Reply

Your email address will not be published. Required fields are marked *

READ MORE CANNABIS NEWS
Archives
Categories

NYCA I MO I MA I COMN I OHNJ I ALAK I AZ I AR I CT I DE I FL I GA I HI I ID I IL I IN I IA I KS I KY I LA I ME I MD I MI I MS I MT I NE I NV I NH I NC I ND I OK I OR I PA I RI I SC I SD I TN I TX I UT I VT I VA I WA I  WV I WI I WY I

FINANCEMEDICALNATIONAL I VETERANSPOLITICSPSYCHEDELICS I EDWIN RUBIS I RETAIL SPOTLIGHT I INDUSTRY I EDUCATION I BUSINESS I CULTURE I  RECREATION I MEDICAL I CULTIVATION I MANUFACTURING I TECHNOLOGY I RESEARCH I INSIGHTS I 

Cannabis Education

What is CBD?